{"publication_id":"5f566366-fb20-4402-ba24-c1117573f97f","screening":{"identified":51,"screened":51,"excluded":0,"included":51,"included_or_retained":51,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"51 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The evidence profile indicates that the current evidence supports metformin's role in glycemic management and suggests possible secondary benefits for colorectal neoplasia prevention and sepsis prognosis, but the anti-aging and cardioprotective case as currently constituted remains incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions under which net benefit accrues have yet to be is consistent with.","The global burden of age-related disease has intensified the search for interventions that might compress morbidity and extend functional independence rather than merely treating individual conditions. Aging itself is the principal risk factor for cardiometabolic disease, neurodegeneration, cancer, and frailty, yet no regulatory framework currently permits approval of a therapy solely for slowing biological aging. Against this backdrop, the question of whether an inexpensive, widely available drug such as metformin could modulate age-related trajectories has captured considerable scientific and public attention. The present moment is notable because multiple trials now underway or recently completed span populations from mid-life adults with metabolic syndrome to older individuals with sarcopenia or frailty, suggesting that the field is actively testing whether metformin effects extend beyond glycemic control. Whether such efforts will yield definitive answers or instead reveal context-dependent trade-offs remains uncertain.","Its glucose-lowering action is mediated primarily through suppression of hepatic gluconeogenesis and enhancement of peripheral insulin sensitivity, effects that have made it the backbone of combination regimens tested across dozens of recent trials. Beyond glycemic control, metformin effects appear to encompass anti-inflammatory and immunomodulatory properties, as evidenced by increased circulating GDF15 levels observed in human experimental studies (Kolnes 2026). The drug is available worldwide, costs pennies per dose in many health systems, and has a well-characterized safety profile, though gastrointestinal intolerance affects a meaningful minority of users and may require formulation adjustments or probiotic co-administration (Ratajczak 2026; Alshadfan 2026). Concerns about vitamin B12 depletion with chronic use (Tahir 2026) and questions regarding safety in advanced chronic kidney disease or very elderly populations (Marchini 2026) temper enthusiasm and underscore that metformin effects must be weighed against its risk profile in any repurposing context. The regulatory and practical advantages of metformin are clear, but whether these advantages translate to demonstrable anti-aging efficacy in humans has been proposed but remains to be confirmed.","The human RCT landscape for metformin effects now extends well beyond glycemic endpoints, though the evidence base remains heterogeneous in design, population, and outcome selection. Metformin effects on cardiometabolic outcomes have been examined in systematic reviews and meta-analyses of trials enrolling predominantly white, overweight adults aged 65 years or younger with poor glycemic control (Griffin 2017), limiting generalizability to older or more diverse populations. In prediabetes, a Bayesian network meta-analysis has evaluated multiple anti-prediabetic drugs including metformin, though effect estimates remain imprecise (Wu 2026). Functional-endpoint trials are now emerging, including a proof-of-concept RCT assessing metformin effects on physical performance in older adults with sarcopenia and prefrailty (Rennie 2022), and a planned study in polycystic ovary syndrome targeting metabolic and reproductive outcomes (Hautamaki 2026). The diversity of ongoing trials is encouraging, yet the predominance of surrogate rather than hard clinical endpoints means that the clinical significance of metformin effects on aging remains uncertain.","Several unresolved questions complicate any synthesis of metformin effects across the aging-relevant evidence base. Mechanistic translation from cell and animal models to human aging biology remains incomplete, as AMPK activation, mTOR inhibition, and mitochondrial effects demonstrated in preclinical systems may not scale proportionally or may produce context-dependent trade-offs in human tissues. Metformin effects on insulin sensitivity appear to differ between rest and exercise conditions, with evidence suggesting that the drug may attenuate exercise-induced metabolic adaptations in adults at risk for metabolic syndrome (Malin 2026), raising the possibility that co-prescription with lifestyle interventions could yield paradoxical outcomes. Population specificity is another critical gap: most trial data derive from type 2 diabetes cohorts, yet repurposing for aging would target broader, often non-diabetic populations, and pregnancy, pediatric, and very elderly contexts introduce distinct risk-benefit calculations (Brinkmann 2025; Newman 2026; Schoenaker 2026). Dose-response relationships for non-glycemic endpoints remain poorly characterized, and the question of whether metformin effects require chronic exposure or can be detected with shorter treatment durations has not been systematically addressed. The translation question is critical: whether these diabetic-population benefits extend to normoglycemic older adults is being addressed by trials such as MET-PREVENT, which targets sarcopenia and physical prefrailty (Rennie 2022). Metabolic syndrome risk modification has been explored in exercise-training paradigms, though metformin attenuated some insulin-sensitivity adaptations in at-risk adults (Malin 2026), illustrating that Metformin Effects may operate differently depending on metabolic context.","Claims were retained only when their numeric value, endpoint, and study label could be reconciled with the source record. Evidence was grouped by outcome class, study design, direction of effect, and clinical directness. Cross-paper tensions were summarized when two retained findings addressed related outcomes but differed in direction, directness, population, comparator, or follow-up. Records that lacked a traceable endpoint, citation, or study identity were excluded from main-text inference and kept in the supplementary audit trail when available.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","The dose-response meta-analytic signal in Shen 2025 suggests that the protective association for colorectal neoplasms may be related to cumulative metformin exposure, an inference supported by the inclusion of dose as a variable in the analysis. However, without the underlying pharmacokinetic data from the trials included in Shen 2025's meta-analysis, it is impossible to correlate specific plasma concentrations with the observed clinical effect. The mechanistic link between oral dose, systemic exposure, and the downstream chemopreventive effect remains an area requiring further direct investigation."]}